Funding for this research was provided by:
Horizon 2020 (733100)
Innovative Medicines Initiative (853995)
Deutsche Forschungsgemeinschaft (ExC 2167)
Universitätsklinikum Schleswig-Holstein - Campus Kiel
Received: 11 January 2022
Accepted: 2 September 2022
First Online: 24 September 2022
: The complete study was performed in accordance with the Declaration of Helsinki and approved by the ethics committee of the Christian-Albrechts-Universität zu Kiel (A 124/14 and AZ 156/03-2/13). All participating subjects of the study provided written informed consent.
: Not applicable
: Stefan Schreiber has been a consultant for AbbVie, Bristol Myers Squibb, Boehringer Ingelheim, Ferring, Genentech/Roche, Janssen, Lilly, Medimmune/AstraZeneca, Novartis, Merck Sharp Dohme, Pfizer, Protagonist, Sanofi, Takeda, Theravance, and UCB and is a paid speaker for AbbVie, Ferring, Janssen, Merck Sharp Dohme, Novartis, Takeda, and UCB. Philip Rosenstiel has been a consultant for Takeda and Omass. All other authors declare no competing interests.